3-甲基苯并呋喃-2-碳酰氯 | 2256-86-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 中文名称: 3-甲基苯并呋喃-2-碳酰氯
• 中文别名: 3-甲基-2-苯并呋喃羰酰氯
• 英文名称: 3-methylbenzofuran-2-carbonyl chloride
• 英文别名: 3-methyl-1-benzofuran-2-carbonyl chloride
• CAS: 2256-86-2
• 化学式: C₁₀H₇ClO₂
• mdl: MFCD01940394
• 分子量: 194.617
• InChiKey: QEULGCOIYWPYIL-UHFFFAOYSA-N

物化性质

• 熔点：
  72-77 °C (lit.)
• 沸点：
  119-121 °C(Press: 4 Torr)
• 密度：
  1.305±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  常温常压下稳定，避免与水源或氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2932999099
• WGK Germany：
  3
• 危险品运输编号：
  UN 3261 8/PG 2
• 储存条件：
  密封储存，存放在阴凉干燥的库房中，并远离水源。

SDS

Name:	3-Methylbenzofuran-2-carbonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	2256-86-2

Section 1 - Chemical Product MSDS Name:3-Methylbenzofuran-2-carbonyl chloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2256-86-2	3-Methylbenzofuran-2-carbonyl chloride	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2256-86-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white to light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 70 - 74 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H7ClO2
Molecular Weight: 194.62

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2256-86-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Methylbenzofuran-2-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: II
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 2256-86-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2256-86-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2256-86-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3-甲基苯并呋喃-2-碳酰氯可用作医药合成中的中间体，并可用于合成其他具有相同母核结构的活性化合物。

反应信息

• 作为反应物：
  描述：

  3-甲基苯并呋喃-2-碳酰氯 在 lithium aluminium tetrahydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 (2E)-N-甲基-N-[(3-甲基-2-苯并呋喃基)甲基]-3-(5,6,7,8-四氢-7-氧代-1,8-萘啶-3-基)-2-丙烯酰胺
  参考文献：
  名称：

  WO2008/98374

  摘要：

  公开号：
• 作为产物：
  描述：

  2-amino-6-(benzyloxy)-3-methylbenzoic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以91%的产率得到3-甲基苯并呋喃-2-碳酰氯
  参考文献：
  名称：

  [EN] COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
  [FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES PERMETTANT DE MODULER LE CFTR

  摘要：

  本公开涉及揭示的化合物，可以调节，例如，解决CFTR活性细胞处理中的潜在缺陷。

  公开号：

  WO2017062581A1

文献信息

• Palladium-catalysed carboformylation of alkynes using acid chlorides as a dual carbon monoxide and carbon source
  作者：Yong Ho Lee、Elliott H. Denton、Bill Morandi

  DOI：10.1038/s41557-020-00621-x

  日期：2021.2

  Hydroformylation, a reaction that installs both a C–H bond and an aldehyde group across an unsaturated substrate, is one of the most important catalytic reactions in both industry and academia. Given the synthetic importance of creating new C–C bonds, the development of carboformylation reactions, wherein a new C–C bond is formed instead of a C–H bond, would bear enormous synthetic potential to rapidly

  加氢甲酰化是一种在不饱和底物上同时安装 C-H 键和醛基的反应，是工业界和学术界最重要的催化反应之一。鉴于创造新的 C-C 键的合成重要性，发展碳甲酰化反应，其中形成新的 C-C 键而不是 C-H 键，将具有巨大的合成潜力，可以在有价值的合成中迅速增加分子的复杂性醛类。然而，利用外源 CO 源的四组分反应固有的苛刻复杂性使得直接碳甲酰化反应的发展成为一项艰巨的挑战。在这里，我们描述了一种钯催化策略，该策略使用现成的芳酰氯作为碳亲电试剂和 CO 源，与空间拥挤的氢硅烷串联，进行炔烃的立体选择性碳甲酰化。将该协议扩展到四种化学发散性羰基化，进一步突出了该策略在羰基化化学中提供的创造性机会。
• N-Substituted homopiperazine barbiturates as gelatinase inhibitors
  作者：Jun Wang、Carlos Medina、Marek W. Radomski、John F. Gilmer

  DOI：10.1016/j.bmc.2011.06.055

  日期：2011.8

  12-O-tetradecanoylphorbol-13-acetate (PMA)-stimulated HT-1080 cells as well as using recombinant human MMPs. N-Acyl homopiperazine compounds were found to be potent inhibitors of the gelatinases (range in nM) and generally more potent than the corresponding piperazine analogues. The panel of N-acyl homopiperazines was enlarged in order to exploit differences between the gelatinases at the S2′ site in order to design

  基质金属蛋白酶涉及广泛的病理生理过程，并且一直在积极寻求针对这些酶的有效选择性抑制剂。5,5-二取代的巴比妥酸盐有希望成为抑制剂，在体内是稳定的，并且对明胶酶（MMP-2和MMP-9）具有相对选择性。在本文中，我们描述了5-哌嗪和-高哌嗪取代的巴比妥酸酯的合成。使用来自12 - O-十四烷酰phorbol-13-乙酸盐（PMA）刺激的HT-1080细胞的上清液以及使用重组人MMP ，评估了这些化合物作为明胶酶抑制剂的活性。ñ发现酰基高哌嗪化合物是明胶酶的有效抑制剂（范围为nM），通常比相应的哌嗪类似物更有效。N-酰基高哌嗪的面板被扩大，以便利用S2'位点的明胶酶之间的差异，以设计MMP-2-或MMP-9-选择性抑制剂。该组化合物表现出一位数的纳摩尔浓度，并且在两种酶之间具有一定的选择性。代表性的有效化合物是癌细胞迁移的有效抑制剂。
• Pd(II)-Catalyzed Arylation and Intramolecular Amidation of γ-C(sp³)–H Bonds: En Route to Arylheteroarylmethane and Pyrrolidone Ring Annulated Furan/Thiophene Scaffolds
  作者：Ramarao Parella、Srinivasarao Arulananda Babu

  DOI：10.1021/acs.joc.7b00582

  日期：2017.7.21

  (1a–e) were derived from their corresponding carboxylic acids and bidentate directing groups. These compounds were then used as substrates to investigate the arylation and successive arylation/intramolecular amidation of the γ-C(sp3)–H bonds. The γ-C(sp3)–H arylation arose from the Pd(II)-catalyzed reactions of these compounds with aryl iodides with reaction periods of 4–24 h (except a few reactions

  我们报告了P​​d（II）催化的，双齿指导基团（BDG）辅助的芳基化和连续的芳基化/γ-C（sp 3）–H键的芳基化。Pd（II）催化的BDG辅助羧酸的C–H活化和功能化，羧酸的β-C（sp 3）–H键，但是仅有少数报道涉及BDG指导的功能化-C（sp 3）–H键的数量。各种3-甲基噻吩/呋喃-2-羧酰胺（1a – e）衍生自其相应的羧酸和二齿导向基团。然后将这些化合物用作底物以研究γ-C（sp 3）– H键。γ-C（sp 3）-H芳基化反应是由这些化合物与芳基碘化物在Pd（II）催化下反应的，反应时间为4-24小时（少数反应需要36或48小时）。值得注意的是，这些反应导致了各种非对称二芳基甲烷的支架，例如噻吩/呋喃类arylheteroarylmethanes（建设3 - 6）。将反应时间延长至48–70 h会导致连续的γ-C（sp 3）–H芳基化/分子内酰胺化，以及C–C和C–N键的构
• Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis
  作者：Shaohua Hou、Xiping Yang、Yu Tong、Yuejing Yang、Quanwei Chen、Boheng Wan、Ran Wei、Yuchen Wang、Yanmin Zhang、Bo Kong、Jianhang Huang、Yadong Chen、Tao Lu、Qinghua Hu、Ding Du

  DOI：10.1016/j.ejmech.2020.113114

  日期：2021.2

  compound 19 with a novel indole-2-carboxamide hinge scaffold. Compound 19 displays potent anti-ASK1 kinase activity and stronger inhibitory effect on ASK1 in AP1-HEK293 cells than previously described ASK1 inhibitor GS-4997. Besides improved in vitro activity, compound 19 also exhibits an appropriate in vivo PK profile. In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound

  凋亡信号调节激酶1（ASK1）是丝裂原激活的蛋白激酶（MAPK）家族的成员，与许多人类疾病有关。在这里，我们描述了命中化合物7的结构优化，并进行了进一步的结构-活性关系（SAR）研究，从而开发了带有新型吲哚-2-羧酰胺铰链支架的化合物19。与先前描述的ASK1抑制剂GS-4997相比，化合物19在AP1-HEK293细胞中显示出强大的抗ASK1激酶活性和对ASK1的更强抑制作用。除了改善体外活性外，化合物19还具有适当的体内活性PK配置文件。在右旋糖酐硫酸钠（DSS）诱导的溃疡性结肠炎（UC）小鼠模型中，化合物19显示出显着的抗UC功效，并显着减轻了DSS诱导的体重减轻，结肠缩短，疾病活动指数（DAI）升高和炎症结肠组织中的细胞浸润。从机理上讲，化合物19抑制ASK1-p38 / JNK信号通路的磷酸化，并抑制炎症细胞因子的过表达。这些发现共同表明，ASK1抑制剂可以潜在地用作UC的治疗策略。
• [EN] PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE<br/>[FR] DÉRIVÉS DE TYPE PROMÉDICAMENT DU (E)-N-MÉTHYL-N-((3-MÉTHYLBENZOFURAN-2-YL) MÉTHYL)-3-(7-OXO-5,6,7,8-TÉTRAHYDRO-L,8-NAPHTYRIDIN-3-YL)ACRYLAMIDE
  申请人：AFFINIUM PHARM INC

  公开号：WO2013190384A1

  公开（公告）日：2013-12-27

  In part, the present disclosure is directed to derivatives of (E)-N-methy1-N-(( 3-methylta 1,8-naphthyndin-3-y1)acrylamide compounds with significant solubility, solid state stability and bioavailability profiles. Said compounds have been found to be effective inhibitors of bacterial fatty acid metabolism via the effective inhibition of FabL hi addition, certain compounds are shown to be stable towards gamma radiation sterilization treatments, and are thus well-suited to the production of a sterile formulation for use in the treatment of illnesses caused by bacterial infections.

  在某种程度上，本公开涉及具有显著溶解性、固态稳定性和生物利用度特性的(E)-N-甲基-N-((3-甲基-1,8-萘啶-3-基)丙烯酰胺)衍生物化合物。这些化合物已被发现是细菌脂肪酸代谢的有效抑制剂，通过有效抑制FabL。此外，某些化合物显示出对γ辐射灭菌处理具有稳定性，因此非常适合用于生产用于治疗由细菌感染引起的疾病的无菌制剂。